Latest news
CYTK Q2 Earnings Top Estimates, Myqorzo Uptake Strong - Yahoo FinanceYahoo Finance · Fri, 07 Aug 2026 18:22:00 GMTCytokinetics: Strong MYQORZO Launch and Upcoming Catalysts Support Buy Rating and Unchanged $140 Price Target - TipRanksTipRanks · Fri, 07 Aug 2026 16:03:00 GMTCytokinetics (NASDAQ:CYTK) Beats Q2 Estimates on Strong MYQORZO Launch - ChartMillChartMill · Thu, 06 Aug 2026 20:49:51 GMTCytokinetics Reports Second Quarter 2026 Financial Results and Provides Business Update - The Manila TimesThe Manila Times · Thu, 06 Aug 2026 20:13:57 GMT